

## **INDEPENDENT AUDITOR'S REPORT**

### **To the Members of BACC Health Care Private Limited Report on the Audit of the Ind AS Financial Statements**

We have audited the accompanying Ind AS financial statements of BACC Health Care Private Limited (“the Company”), which comprise the Balance Sheet as at 31 March 2018, the Statement of Profit and Loss, the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and summary of the significant accounting policies and other explanatory information (herein after referred to as “Ind AS financial statements”).

#### **Management's Responsibility for the Ind AS Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 (“the Act”) with respect to the preparation of these Ind AS financial statements that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

**Independent Auditor's Report (continued)**  
**Auditor's Responsibility**

Our responsibility is to express an opinion on these Ind AS financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit of the Ind AS financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Ind AS financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Ind AS financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the Ind AS financial statements.

We are also responsible to conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify the opinion. Our conclusions are based on the audit evidence obtained up to the date of the auditor's report. However, future events or conditions may cause an entity to cease to continue as a going concern.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS financial statements.

**Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31 March 2018, its profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

### **Other Matters**

As fully explained in note 38 to the Ind AS financial statements, the Company has given effect to the Scheme of arrangement ('Scheme') approved by Regional Director, Ministry Of Corporate Affairs, South East Region vide its order dated 29 January 2018. The Company has given effect to the scheme which is merger of DKR HealthCare Private Limited ("DKR") with the Company from the appointed date specified in the Scheme i.e. 1 April 2017. The accounting treatment is in line with the accounting treatment as prescribed in Appendix C of Ind AS 103, 'Business Combination. This being a common control entity, the financial information has been re-stated from the beginning of the preceding period, i.e. 1 April 2016.

Corresponding figures for the year ended 31 March 2017 of the Ind AS financial statements have been audited by the predecessor auditor who expressed an unmodified opinion dated 23 May 2017. The figures for year ended 31 March 2017 of DKR were audited by the predecessor auditor who expressed an unmodified opinion dated 19 May 2017.

Our opinion on the Ind AS financial statements is not modified in respect of the above matters.

### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) The Balance Sheet, the Statement of Profit and Loss, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account.
  - d) In our opinion, the aforesaid Ind AS financial statements comply with the Indian Accounting Standards prescribed under section 133 of the Act.
  - e) On the basis of the written representations received from the directors as on 31 March 2018 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2018 from being appointed as a director in terms of Section 164(2) of the Act.
  - f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

## **Report on Other Legal and Regulatory Requirements (Continued)**

- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
  - iv. The disclosures in the Ind AS financial statements regarding holdings as well as dealings in specified bank notes during the period from 8 November 2016 to 30 December 2016 have not been made since they do not pertain to the financial year ended 31 March 2018. However, amounts as appearing in the audited Ind AS financial statements for the period ended 31 March 2017 have been disclosed.

*for BSR & Co. LLP*

*Chartered Accountants*

Firm's registration number: 101248W/W-100022

**Amit Somani**

*Partner*

Membership number: 060154

Place: Bengaluru

Date: 8 August 2018

## **Annexure- A to the Independent Auditor's Report**

The Annexure referred to in paragraph 1 in 'Report on Other Legal and Regulatory Requirements' of the Independent Auditor's Report to the members of BACC Health Care Private Limited ("the Company") on the Ind AS Financial Statements for the year ended 31 March 2018. We report that:

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment.
- (b) The Company has a regular programme of physical verification of its property, plant and equipment by which all property, plant and equipment are verified once in every year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, entire fixed assets were verified during the current year and no material discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no immovable properties held in the name of the Company.
- (ii) The inventory have been physically verified by the Management during the year. In our opinion, the frequency of such verification is reasonable. The discrepancies noticed on verification between the physical stock and the book records were not material.
- (iii) The Company has not granted any loans, secured or unsecured to Companies, Firms, Limited liability Partnerships('LLP') or other parties covered in the register maintained under section 189 of the Companies Act, 2013 ('the Act'). Accordingly, paragraph 3(iii) of the Order is not applicable to the Company.
- (iv) According to the information and explanations given to us, the Company has not granted any loan or made any investment or provided any guarantee or security to the parties covered under section 185 and 186 of the Act. Accordingly, paragraph 3(iv) of the Order is not applicable to the Company.
- (v) According to the information and explanations given to us, the Company has not accepted any deposits. Accordingly, paragraph 3(v) of the Order is not applicable to the Company.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014 as amended, prescribed by the Central Government under section 148 of the Act and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not made a detailed examination of such records.
- (vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including employee's provident fund, employee's state insurance, Income tax, sales tax, service tax, value added tax, goods and service tax, cess and any other material statutory dues have been regularly deposited with the appropriate authorities though there

## **BACC Health Care Private Limited**

### **Annexure A to the Independent Auditor's report (continued)**

has been a slight delay in a few cases. As explained to us, the Company did not have any dues on account of duty of excise and custom duty.

According to the information and explanations given to us, no undisputed amounts payable in respect of employee's provident fund, employee's state insurance, income tax, sales tax, service tax, value added tax, goods and service tax, cess and other material statutory dues were in arrears as at 31 March 2018 for a period of more than six months from the date they became payable.

- (b) According to the information and explanations given to us, there are no dues of Income Tax, Sales Tax, Service Tax, Value Added Tax and Goods and Service Tax which have not been deposited with the appropriate authorities on account of any dispute.
- (viii) According to the information and explanation given to us, the Company has not defaulted in the repayment of loans or borrowings to financial institutions and banks. The Company has not issued any debentures and did not have any borrowings from government.
- (ix) According to the information and explanations given to us and based on examination of the records of the Company, the term loans obtained during the year were applied for the purpose for which they were obtained. The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year.
- (x) According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year of our audit.
- (xi) According to the information and explanations given to us and based on examination of the records of the Company, the Company has not paid managerial remuneration during the year. Accordingly the provisions of Section 197 read with Schedule V to the Act are not applicable to the Company.
- (xii) In our opinion and according to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, paragraph 3(xii) of the Order is not applicable.
- (xiii) According to the information and explanations given to us and based on our examination of the records of the Company, all transactions with the related parties are in compliance with sections 188 of the Act where applicable and details of such transactions have been disclosed in the Ind AS financial statements as required by the applicable accounting standards. The provision of Section 177 of the Act is not applicable to the Company.
- (xiv) According to the information and explanations give to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, paragraph 3(xiv) of the Order is not applicable.
- (xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Order is not applicable.

**BACC Health Care Private Limited**

**Annexure A to the Independent Auditor's report (continued)**

- (xvi) According to the information and explanations given to us, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

*for B S R & Co. LLP*

*Chartered Accountants*

Firm's registration number: 101248W/W-100022

**Amit Somani**

*Partner*

Membership number: 060154

Place: Bengaluru

Date: 8 August 2018

**Annexure - B to the Independent Auditor's Report of even date on the Ind AS financial statements of BACC Health Care Private Limited**

**Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting with reference to Ind AS financial statement of BACC Health Care Private Limited ("the Company") as of 31 March 2018 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

**Management's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

**Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, both issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.



## **Annexure B to the Independent Auditor's Report (continued)**

### **Meaning of Internal Financial Controls Over Financial Reporting**

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Ind AS financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that:

1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of Ind AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the Company; and
3. provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the Ind AS financial statements.

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting with reference to Ind AS financial statements and such internal financial controls over financial reporting were operating effectively as at 31 March 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

*for B S R & Co. LLP*

*Chartered Accountants*

Firm's registration number: 101248W/W-100022

**Amit Somani**

*Partner*

Membership number: 060154

Place: Bengaluru

Date: 8 August 2018

**BACC HEALTH CARE PRIVATE LIMITED**

(Rs. in Million)

Balance Sheet as at	Note No	31 March 2018	31 March 2017 (Restated*)
<b>Assets</b>			
<b>Non-current assets</b>			
Property, plant and equipment	3	372.47	295.47
Capital work-in-progress	3	27.62	36.43
Goodwill	4	-	0.13
Financial assets			
Loans	5	21.38	22.90
Other financial assets	6	9.47	27.81
Income tax assets (net)	7	5.18	4.16
Other non-current assets	8	16.52	20.39
<b>Total non-current assets</b>		<b>452.64</b>	<b>407.29</b>
<b>Current assets</b>			
Inventories	9	12.27	11.17
Financial assets			
Trade receivables	10	17.96	18.32
Cash and cash equivalents	11 (a)	33.27	26.00
Bank balance other than cash and cash equivalents above	11 (b)	25.00	15.50
Loans	5	4.78	1.00
Other financial assets	6	1.62	-
Other current assets	8	11.81	7.77
<b>Total current assets</b>		<b>106.71</b>	<b>79.76</b>
<b>Total assets</b>		<b>559.35</b>	<b>487.05</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Equity share capital	12	0.94	0.94
Other equity	13	395.90	355.36
<b>Total equity</b>		<b>396.84</b>	<b>356.30</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Financial liabilities			
Borrowings	14	17.41	15.57
Provisions	16	5.79	3.44
Deferred tax liabilities (Net)	17	9.55	7.53
Other non-current liabilities	18	6.94	5.92
<b>Total non-current liabilities</b>		<b>39.69</b>	<b>32.46</b>
<b>Current liabilities</b>			
Financial liabilities			
Trade payables	19	47.46	46.13
Other financial liabilities	15	62.09	40.73
Provisions	16	2.82	2.09
Other current liabilities	18	10.45	9.34
<b>Total current liabilities</b>		<b>122.82</b>	<b>98.29</b>
<b>Total liabilities</b>		<b>162.51</b>	<b>130.75</b>
<b>Total equity and liabilities</b>		<b>559.35</b>	<b>487.05</b>

Significant accounting policies 2.2

\* Refer note 38

The accompanying notes are an integral part of these Ind AS financial statements

As per reports of even date attached

for **B S R & Co. LLP**

Chartered Accountants

Firm's registration number: 101248W/W -100022

for and on behalf of the Board of Directors of

**BACC Health Care Private Limited**

**Amit Somani**

Partner

Membership Number: 060154

**Dr. B S Ajaikumar**

Director

DIN: 00713779

**Dr. Kamini A.Rao**

Director

DIN: 01075263

Place : Bengaluru

Date : 8 August 2018

Place : Bengaluru

Date : 8 August 2018

Place : Bengaluru

Date : 8 August 2018

**BACC HEALTH CARE PRIVATE LIMITED**

(Rs. in Million)

Statement of profit and loss for the years ended	Note No.	31 March 2018	31 March 2017 (Restated*)
<b>Income</b>			
Revenue from operations	20	669.03	589.50
Other income	21	2.90	5.75
<b>Total income</b>		<b>671.93</b>	<b>595.25</b>
<b>Expenses</b>			
Purchases of medical and non-medical items		153.74	140.39
Changes in inventories	22	(1.10)	(0.94)
Employee benefits expense	23	98.96	90.64
Finance costs	24	12.51	11.12
Depreciation and amortisation expense	3 & 4	43.70	27.91
Other expenses	25	304.01	249.79
<b>Total expenses</b>		<b>611.82</b>	<b>518.91</b>
<b>Profit before tax</b>		<b>60.11</b>	<b>76.34</b>
<b>Tax expense</b>			
Current tax	26.1	18.03	22.77
Deferred tax	26.1	2.09	1.76
<b>Total tax expense</b>		<b>20.12</b>	<b>24.53</b>
<b>Profit for the year</b>		<b>39.99</b>	<b>51.81</b>
<b>Other comprehensive income/ (expense)</b>			
Items that will not be reclassified subsequently to profit or loss			
Remeasurements of the defined benefit plans	31.2	(0.21)	(0.01)
Income tax on the above		0.07	-
Other comprehensive income/ (expense) for the year, net of income tax		<b>(0.14)</b>	<b>(0.01)</b>
<b>Total comprehensive income for the year</b>		<b>39.85</b>	<b>51.80</b>
<b>Earnings per equity share (nominal value of share Rs. 10)</b>			
Basic and diluted (in Rs.)	28	427.34	553.66
Significant accounting policies	2.2		

\* Refer note 38

The accompanying notes are an integral part of these Ind AS financial statements

As per reports of even date attached

for **B S R & Co. LLP**

Chartered Accountants

Firm's registration number: 101248W/W -100022

for and on behalf of the Board of Directors of

**BACC Health Care Private Limited**

**Amit Somani**

Partner

Membership Number: 060154

**Dr. B S Ajaikumar**

Director

DIN: 00713779

**Dr. Kamini A. Rao**

Director

DIN: 01075263

Place : Bengaluru

Date : 8 August 2018

Place : Bengaluru

Date : 8 August 2018

Place : Bengaluru

Date : 8 August 2018

**BACC HEALTH CARE PRIVATE LIMITED**

(Rs. in Million)

Cash Flow Statement for the years ended	Note No	31 March 2018	31 March 2017 (Restated*)
<b>A. Cash flows from operating activities</b>			
Profit before tax		60.11	76.34
<b>Adjustments for:</b>			
Provision for doubtful trade receivables and deposits		1.99	2.14
Finance costs		12.51	11.12
Interest income		(0.94)	(3.67)
Depreciation and amortisation		43.70	27.91
<b>Movements in working capital:</b>			
Change in trade receivables		(1.64)	(6.54)
Change in inventories		(1.10)	(0.94)
Changes in loans, other financial assets and other assets		(5.70)	(0.58)
Change in trade payables, current and financial liabilities		3.48	18.71
Change in provisions		2.88	2.95
<b>Cash generated from operations</b>		<b>115.29</b>	<b>127.44</b>
Income taxes paid (net of refunds)		(19.05)	(16.38)
<b>Net cash generated by operating activities (A)</b>		<b>96.24</b>	<b>111.06</b>
<b>Cash flows from investing activities</b>			
Payment to acquire financial assets		-	(6.76)
Investment in margin money deposits		-	(4.34)
Proceeds from margin money matured		8.00	2.00
Interest received		1.78	1.93
Advance given to related parties		-	2.81
Acquisition of property, plant and equipment		(89.04)	(110.68)
<b>Net cash used in investing activities (B)</b>		<b>(79.26)</b>	<b>(115.04)</b>
<b>Cash flows from financing activities</b>			
Proceeds from borrowings		34.06	28.67
Repayment of borrowings		(31.20)	(1.12)
Interest and other borrowing costs		(12.57)	(10.89)
<b>Net cash (used in) / generated by financing activities (C)</b>		<b>(9.71)</b>	<b>16.66</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>		<b>7.27</b>	<b>12.68</b>
Cash and cash equivalents at the beginning of the year	11	26.00	13.32
<b>Cash and cash equivalents at the end of the year</b>	11	<b>33.27</b>	<b>26.00</b>

## Reconciliation of movement of liabilities to cash flow arising from financing activities

Particulars	Term loans from banks	Total
Debt as at 1 April 2017	46.77	46.77
Interest accrued but not due	0.40	0.40
	<b>47.17</b>	<b>47.17</b>
Cash flows including interest paid	(9.71)	(9.71)
Ind AS adjustment with respect to unamortised loan processing charges	(1.02)	(1.02)
Interest expenses	12.51	12.51
Interest accrued but not due as on 31 March 2018	(0.34)	(0.34)
<b>Debt as at 31 March 2018</b>	<b>48.61</b>	<b>48.61</b>

Significant accounting policies

2.2

\* Refer note 38

The accompanying notes are an integral part of these Ind AS financial statements

As per reports of even date attached

*for* **B S R & Co. LLP**

Chartered Accountants

Firm's registration number: 101248W/W -100022

*for* and on behalf of the Board of Directors of**BACC Health Care Private Limited****Amit Somani**

Partner

Membership Number: 060154

**Dr. Kamini A. Rao**

Director

DIN: 00713779

**Dr. Kamini A. Rao**

Director

DIN: 01075263

Place : Bengaluru

Date : 8 August 2018

Place : Bengaluru

Date : 8 August 2018

Place : Bengaluru

Date : 8 August 2018

**BACC HEALTH CARE PRIVATE LIMITED****Statement of changes in equity for the years ended 31 March 2018 and 31 March 2017****a. Equity share capital**

	No of shares	Rs. in Million
<b>Balance as at 01 April 2016</b>	93,578	0.94
Changes in equity share capital during the year	-	-
<b>Balance as at 31 March 2017</b>	93,578	0.94
Changes in equity share capital during the year	-	-
<b>Balance as at 31 March 2018</b>	<b>93,578</b>	<b>0.94</b>

**b. Other equity**

(Rs. in Million)

	Reserves and surplus				Items of other comprehensive income	Total other equity	
	Note No.	Securities premium	General reserve	Capital redemption reserve	Retained earnings (Restated) (Refer note 38)		Remeasurements of the defined benefit plan
<b>Balance as at 01 April 2016</b> (Restated, refer note 38)		<b>109.92</b>	<b>0.60</b>	<b>0.15</b>	<b>192.42</b>	<b>0.47</b>	<b>303.56</b>
Profit for the year (Restated, refer note 38)		-	-	-	51.81	-	51.81
Other comprehensive income for the year, net of income tax (Restated, refer note 38)		-	-	-	-	(0.01)	(0.01)
<b>Total comprehensive income for the year</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>51.81</b>	<b>(0.01)</b>	<b>51.80</b>
<b>Balance as at 31 March 2017</b>		<b>109.92</b>	<b>0.60</b>	<b>0.15</b>	<b>244.23</b>	<b>0.46</b>	<b>355.36</b>
Profit for the year		-	-	-	39.99	-	39.99
Other comprehensive income for the year, net of income tax		-	-	-	-	(0.14)	(0.14)
Fair valuation of corporate guarantee given by holding company		-	-	-	0.69	-	0.69
<b>Total comprehensive income for the year</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>40.68</b>	<b>(0.14)</b>	<b>40.54</b>
<b>Balance as at 31 March 2018</b>		<b>109.92</b>	<b>0.60</b>	<b>0.15</b>	<b>284.91</b>	<b>0.32</b>	<b>395.90</b>

**Security premium**

Securities premium is used to record the premium received on issue of shares. It is utilised in accordance with the provisions of the Companies Act, 2013.

**General reserve**

General reserve is used from time to time to transfer profits from retained earnings for appropriate purposes.

**Capital redemption reserve**

Represents the reserve created to the extent of the face value of the equity shares on buy back of 15,000 equity shares during the earlier year ending 31 March 2012.

Significant accounting policies 2.2

The accompanying notes are an integral part of these Ind AS financial statements

As per reports of even date attached

**for B S R & Co. LLP**

*Chartered Accountants*

Firm's registration number: 101248W/W -100022

*for* and on behalf of the Board of Directors of

**BACC Health Care Private Limited**

**Amit Somani**

*Partner*

Membership Number: 060154

Place : Bengaluru

Date : 8 August 2018

**Dr. Kamini A. Rao**

*Director*

DIN: 00713779

Place : Bengaluru

Date : 8 August 2018

**Dr. Kamini A. Rao**

*Director*

DIN: 01075263

Place : Bengaluru

Date : 8 August 2018

**BACC HEALTH CARE PRIVATE LIMITED****Notes to the Ind AS financial statements for the year ended 31 March 2018**

1 BACC Healthcare Private Limited (the Company) is engaged in setting up and managing hospitals for infertility treatment including endoscopic and gynaecology procedures. The Company has its registered office at #7, East Park Road, Kumara Park East, Bengaluru - 560 001. The Company also has its hospital units in other parts of Bangalore and operates out of Delhi, Mumbai, Ahmedabad and Chandhigarh.

**2.1 Basis of preparation of the financial statements****a) Statement of compliance**

These financial statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016, as applicable.

**b) Functional and presentiaon currency**

These financial statements are presented in Indian Rupees (Rs), which is also the Company's functional currency. All amounts are in Indian Rupees million except share data and per share data, unless otherwise stated.

**(c) Basis of measurement**

The financial statements have been prepared on the historical cost basis except for the following items:

Items	Measurement
Net defined benefit (asset)/ liability	Fair value of plan assets less present value of defined benefit obligations

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

**(d) Use of estimates and judgements**

In preparing these financial statements, management of the company has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

The following are the key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the reporting period that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

*Judgements*

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognised in the financial statements is included in the following notes:

Note 30 - Lease arrangements

Note 32 - Financial instruments

**Assumptions and estimate uncertainties**

Information about assumptions and estimation uncertainties that have significant risk of resulting in a material adjustment in the year ending 31 March 2018 is included in the following notes:

Note -3 - Useful life of property, plant and equipment and intangible asset.

Note -31 - Employee benefit plans: key actuarial assumptions;

**(e) Measurement of fair values**

The Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. The Company has an established control framework with respect to the measurement of fair values. This includes a valuation team that has overall responsibility for overseeing all significant fair value measurement, including level 3 fair values, and reports directly to the chief financial officer. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

**(f) Business combinations**

In accordance with Ind AS 103, "Business combinations" the Company accounts for the business combinations using the acquisition method when control is transferred to the Company. The consideration transferred for the business combination is generally measured at fair value as at the date the control is acquired (acquisition date), as are the net identifiable assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognised in Other comprehensive income (OCI) and accumulated in equity as capital reserve if there exists clear evidence of the underlying reasons for classifying the business combination as resulting in a bargain purchase; otherwise the gain is recognised directly in equity as capital reserve. Transaction costs are expensed as incurred, except to the extent related to the issue of debt or equity securities.

The consideration transferred does not include amounts related to the settlement of pre-existing relationships with the acquiree. Such amounts are generally recognised in the Statement of Profit or Loss.

Any contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that meets the definition of financial instrument is classified as equity, then its not remeasured subsequently and settlement is accounted for within equity. Other contingent consideration is remeasured at fair value at each reporting date and changes in the fair value of the contingent consideration are recognised in profit or loss.

**2.2 Summary of significant accounting policies**

**(a) Revenue recognition**

**Medical services**

Revenue primarily comprises fees charged for inpatient and outpatient hospital services. Services include charges for accommodation, medical professional services, equipment, radiology, laboratory and pharmaceutical goods used in treatments given to patients. Revenue is recorded net of discounts given to patients during the period in which the hospital service is provided, based upon the estimated amounts due from patients and/or medical funding entities.

**Sale of medical and non-medical items**

Pharmacy sales are recognised when the significant risks and rewards of ownership is transferred to the customer. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

**Other operating income**

Other operating income primarily comprises of reveue from training provided to medical students . Income from such training are recognised over the period of training.

**Interest income**

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Unbilled revenue is recorded for the services rendered and invoice is not raised for the service.

**(b) Leases**

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

Assets held under finance leases are initially capitalised as assets of the Company at their fair value at the inception of the lease or, if lower, at the present value of the minimum lease payments. The corresponding liability to the lessor is included in the balance sheet as a deferred payment obligation. Lease payments are apportioned between finance expenses and reduction of the lease obligation so as to achieve a constant rate of interest on the remaining balance of the liability.

Rental expense from operating leases is generally recognised on a straight-line basis over the term of the relevant lease. Where the rentals are structured solely to increase in line with expected general inflation to compensate for the lessor's expected inflationary cost increases, such increases are recognised in the year in which such benefits accrue. Contingent rentals arising under operating leases are recognised as an expense in the period in which they are incurred.

**(c) Foreign currency translation**

Transactions in foreign currencies are translated into the respective functional currencies of the Company at the exchange rates at the dates of the transactions or an average rate approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date.

Exchange differences on monetary items are recognised in the Statement of profit and loss in the period in which they arise except for exchange differences arising from translation of long-term foreign currency monetary items recognised in the financial statements of the Company for the period immediately before the beginning of the first Ind AS financial reporting period (prior to 01 April 2016), as per the previous GAAP, pursuant to the Company's choice of availing the exemption as permitted by Ind AS 101.

Non-monetary assets and liabilities that are measured in terms of historical cost in foreign currencies are not re-translated.

Income and expense items in foreign currency are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used.

**(d) Borrowing costs**

Borrowing costs include:

- (i) interest expense calculated using the effective interest rate method,
- (ii) finance charges in respect of finance leases, and
- (iii) exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs.

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

All other borrowing costs are recognised in the statement of profit and loss in the period in which they are incurred.

**(e) Employee benefits**

*Defined benefit plan*

Payments to defined contribution retirement benefit plans are recognised as an expense when employees have rendered service entitling them to the contributions.

For defined benefit retirement plans, the cost of providing benefits is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each annual reporting period. Remeasurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding net interest), is reflected in the balance sheet with a charge or credit recognised in other comprehensive income in the period in which they occur. The service cost (including current service cost, past service cost, as well as gains and losses on curtailments and settlements) is recognised in the statement of profit and loss in the line item 'Employee benefits expense'. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset. The net interest expense is recognised in the line item 'Finance costs'.

*Defined contribution plan*

A defined contribution plan is post-employment benefit plan under which an entity pays specified contributions to separate entity and has no obligation to pay any further amounts. The Company makes specified obligations towards employee provident fund. The Company's contributions are recognized as an expense in the statement of profit and loss during the period in which the employee renders the related service

*Compensated absences*

The employees can carry-forward a portion of the unutilized accrued compensated absences and utilize it in future service periods or receive cash compensation on termination of employment. Since the employee has unconditional right to avail the leave, the benefit is classified as a short term employee benefit. The Company records an obligation for such compensated absences in the period in which the employee renders the services that increase this entitlement. The obligation is measured on the basis of independent actuarial valuation using the projected unit credit method.

**(f) Taxation**

Income tax expense represents the sum of the tax currently payable and deferred tax.

*Current tax*

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realize the assets and settle the liability on a net basis or simultaneously.

*Deferred tax*

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.



**BACC HEALTH CARE PRIVATE LIMITED****Notes to the Ind AS financial statements for the year ended 31 March 2018**

---

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

Minimum alternative tax ('MAT') paid in accordance with the tax laws, which gives rise to future economic benefits in the form of adjustment of future tax liability, is considered as an asset if there is convincing evidence that the Company will pay normal income tax in future years. Ind AS 12, Income Taxes defines deferred tax to include carry forward of unused tax credits that are carried forward by the entity for a specified period of time. Accordingly, MAT credit entitlement is grouped with deferred tax assets (net) in the balance sheet.

**(g) Property, plant and equipment**

Property, plant and equipment are measured at cost which includes capitalized borrowing costs, less accumulated depreciation and impairment losses, if any. The cost of an item of property, plant and equipment comprises its purchase price, including import duties and other non-refundable taxes or levies, freight, any directly attributable cost of bringing the asset to its working condition for its intended use and estimated cost of dismantling and restoring onsite; any trade discounts and rebates are deducted in arriving at the purchase price. Subsequent expenditures related to an item of tangible fixed asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance. Cost includes expenditures directly attributable to the acquisition of the asset.

The Company depreciates property, plant and equipment over the estimated useful life on a straight-line basis from the date the assets are ready for intended use. Assets acquired under finance lease and leasehold improvements are amortized over the lower of estimated useful life and lease term. The estimated useful lives of assets for the current and comparative period of significant items of property, plant and equipment are as follows:

Estimated useful lives of the assets are as follows:

Asset category	Useful life as per the management	As per schedule II of Companies Act, 2013
Plant and medical equipment	10-15 years	10-15 years
Data processing equipment	3-6 years	3-6 years
Furniture and fixtures	10 years	10 years
Vehicles	8 years	8 years
Office Equipment	5 years	5 years

The cost and related accumulated depreciation are eliminated from the financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the statement of profit and loss. Amounts paid towards the acquisition of property, plant and equipment outstanding as of each reporting date are recognized as capital advance and the cost of property, plant and equipment not ready for intended use before such date are disclosed under capital work- in-progress.

**(h) Intangible assets****(i) Intangible assets acquired separately**

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Amortisation is recognised on a straight-line basis over their estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.

**Useful lives of intangible assets**

Estimated useful lives of the intangible assets are as follows:

Asset category	Useful life
Goodwill	5 years

**(ii) Goodwill**

Goodwill arising on a business combination is initially measured at excess of purchase consideration over fair value of identified net asset taken over. Subsequent measurement is at initial recognition less any accumulated impairment losses.

**(j) Inventories**

Inventories are measured at the lower of cost and net realisable value on the weighted average cost basis. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Cost of inventories comprises of all costs of purchase and other costs incurred in bringing the inventories to their present location, after adjusting for value added tax /good and service tax wherever applicable applying weighted average cost method.

Imported inventories are accounted for at the applicable exchange rates prevailing on the date of transaction.

**(k) Provisions**

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

**Onerous contracts**

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.

**(l) Financial instruments**

**a. Recognition and initial measurement**

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset or financial liability is initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue.

**b. Classification and subsequent measurement**

*Financial assets*

On initial recognition, a financial asset is classified as measured at amortised cost or FVTPL.

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All financial assets not classified as measured at amortised cost as described above are measured at FVTPL. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

*Financial assets: Subsequent measurement and gains and losses*

Financial assets at FVTPL	These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.
Financial assets at amortised cost	These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

*Financial assets: Business model assessment*

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- how the performance of the portfolio is evaluated and reported to the Company's management;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- how managers of the business are compensated – e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the Company's claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

*Financial liabilities: Classification, subsequent measurement and gains and losses*

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

**c. Derecognition**

*Financial assets*

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

*Financial liabilities*

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.

The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in profit or loss.

*Offsetting*

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

**(m) Impairment**

**(i) Financial assets (other than at fair value)**

The Company assesses at each date of balance sheet, whether a financial asset or a group of financial assets is impaired. Ind AS 109 - Financial instrument requires expected credit losses to be measured through a loss allowance. The Company recognises lifetime expected losses for all contract assets and / or all trade receivables that do not constitute a financing transaction. For all other financial assets, expected credit losses are measured at an amount equal to the twelve-month expected credit losses or at an amount equal to the life time expected credit losses if the credit risk on the financial asset has increased significantly, since initial recognition.

**(ii) Non-financial assets**

**(a) Tangible and intangible assets**

Property, plant and equipment and intangible assets with finite life are evaluated for recoverability whenever there is an indication that their carrying amounts may not be recoverable. If any such indication exists, the recoverable amount (i.e. higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for cash generating unit (CGU) to which the asset belongs.

If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognised in the statement of profit and loss.

**(n) Earnings per share**

Basic earnings per share are computed by dividing profit attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period/year.

**(o) Contingent liabilities**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements unless the possibility of an outflow of resources embodying economic benefits is remote.

Contingent liabilities and commitments are reviewed by the management at each balance sheet date.

**(p) Cash flow statement**

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated.

**(q) Cash and cash equivalents**

Cash and cash equivalents include cash in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less.

**2.3 New Accounting standards not yet adopted:**

Ministry of Corporate Affairs ("MCA") through Companies (Indian Accounting Standards) Amendment Rules, 2018 has notified the following new amendments to Ind ASs which the Company has not applied as they are effective for annual periods beginning on or after 01 April 2018:

***Ind AS 115 - Revenue from Contracts with Customers***

On 28 March 2018, the MCA notified the Ind AS 115 Revenue from contract with customers. The core principle of the new standard is that an entity should recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and service. Further, the new standard requires enhanced disclosure about the nature, amount, timing and uncertainty of revenue and cash flow arising from the entity's contract with customers. The effective date for adoption of Ind AS 115 is financial period beginning on or after 01 April 2018.

There is no material impact on account of adoption of Ind AS 115 to the Company's current policy of revenue recognition.

***Ind AS 21 – The effect of changes in foreign Exchange rates***

The amendment clarifies on the accounting of transactions that include the receipt or payment of advance consideration in a foreign currency. The appendix explains that the date of the transaction, for the purpose of determining the exchange rate, is the date of initial recognition of the non-monetary prepayment asset or deferred income liability. If there are multiple payments or receipts in advance, a date of transaction is established for each payment or receipt. The Company is evaluating the impact of this amendment on its Ind AS financial statements.

**BACC HEALTH CARE PRIVATE LIMITED**

Notes to the Ind AS Financial statements (continued)

(Rs. in Million)

**3 Property, plant and equipment and capital work-in-progress**

Description of Assets	Leasehold improvements	Medical equipment	Plant and equipment	Office equipment	Furniture and fixtures	Computers	Vehicles	Total ( A )	Capital work in progress ( B )	Total (A + B)
<b>I. Cost</b>										
Balance as at 01 April 2016	107.40	83.79	50.80	4.60	5.64	7.15	0.24	259.62	15.27	274.89
Additions	28.69	41.95	10.15	1.34	1.25	2.37	-	85.75	64.18	149.93
Disposals	(0.24)	-	-	-	-	-	-	(0.24)	-	(0.24)
Capitalised*	-	-	-	-	-	-	-	-	(43.02)	(43.02)
Balance as at 31 March 2017	135.85	125.74	60.95	5.94	6.89	9.52	0.24	345.13	36.43	381.56
Additions	57.10	42.08	16.07	1.20	0.78	3.40	-	120.63	97.58	218.21
Disposals	(0.02)	-	-	(0.04)	-	-	-	(0.06)	-	(0.06)
Capitalised*	-	-	-	-	-	-	-	-	(106.39)	(106.39)
<b>Balance as at 31 March 2018</b>	<b>192.93</b>	<b>167.82</b>	<b>77.02</b>	<b>7.10</b>	<b>7.67</b>	<b>12.92</b>	<b>0.24</b>	<b>465.70</b>	<b>27.62</b>	<b>493.32</b>
<b>II. Accumulated depreciation</b>										
Balance as at 01 April 2016	5.48	8.82	3.32	1.14	0.88	2.01	0.24	21.89	-	21.89
Eliminated on disposal of assets	-	-	-	-	-	-	-	-	-	-
Depreciation expense	10.75	8.59	4.39	1.13	0.79	2.12	-	27.77	-	27.77
Balance as at 31 March 2017	16.23	17.41	7.71	2.27	1.67	4.13	0.24	49.66	-	49.66
Depreciation expense	22.71	11.62	3.93	1.80	0.62	2.89	-	43.57	-	43.57
<b>Balance as at 31 March 2018</b>	<b>38.94</b>	<b>29.03</b>	<b>11.64</b>	<b>4.07</b>	<b>2.29</b>	<b>7.02</b>	<b>0.24</b>	<b>93.23</b>	<b>-</b>	<b>93.23</b>
<b>Net block as at 31 March 2017</b>	<b>119.62</b>	<b>108.33</b>	<b>53.24</b>	<b>3.67</b>	<b>5.22</b>	<b>5.39</b>	<b>-</b>	<b>295.47</b>	<b>36.43</b>	<b>331.90</b>
<b>Net block as at 31 March 2018</b>	<b>153.99</b>	<b>138.79</b>	<b>65.38</b>	<b>3.03</b>	<b>5.38</b>	<b>5.90</b>	<b>-</b>	<b>372.47</b>	<b>27.62</b>	<b>400.09</b>

\* Includes expenses capitalised of Rs 32.47 million as at 31 March 2018 (31 March 2017, Rs.17.94 million) towards setting up of new hospital units. Refer note 14 for details of charge created on fixed assets.

**4 Intangible assets**

<b>Description of Assets</b>	<b>Goodwill</b>	<b>Total</b>
<b>I. Cost</b>		
As at 1 April 2016	0.70	0.70
Additions	-	-
Balance as at 31 March 2017	0.70	0.70
Additions	-	-
<b>Balance as at 31 March 2018</b>	<b>0.70</b>	<b>0.70</b>
<b>II. Accumulated depreciation and impairment</b>		
Amortisation expense	0.43	0.43
Eliminated on disposal of assets	-	-
Balance as at 01 April 2016	<b>0.43</b>	<b>0.43</b>
		-
Amortisation expense	0.14	0.14
Balance as at 31 March 2017	0.57	0.57
Amortisation expense	0.13	0.13
<b>Balance as at 31 March 2018</b>	<b>0.70</b>	<b>0.70</b>
<b>Net block as at 31 March 2017</b>	<b>0.13</b>	<b>0.13</b>
<b>Net block as at 31 March 2018</b>	<b>-</b>	<b>-</b>

**5 Loans (unsecured, considered good)**

	As at 31 March 2018		As at 31 March 2017	
	Non current	Current	Non current	Current
Security deposits	21.38	3.60	22.90	-
- Considered good	0.60	-	0.60	-
- Considered doubtful	(0.60)	-	(0.60)	-
Advances to employees	-	1.18	-	1.00
	<b>21.38</b>	<b>4.78</b>	<b>22.90</b>	<b>1.00</b>

**6 Other financial assets**

	As at 31 March 2018		As at 31 March 2017	
	Non current	Current	Non current	Current
Term deposits more than 12 months maturity from the reporting date*	8.64	-	23.14	-
Interest accrued but not due on deposits	0.83	-	4.67	-
Unbilled revenue	-	1.62	-	-
	<b>9.47</b>	<b>1.62</b>	<b>27.81</b>	-

\*The above deposits are restrictive as it pertain to margin money given against bank loan.

**7 Income tax assets (net)**

	As at 31 March 2018	As at 31 March 2017
Advance tax (net of provision for tax)	5.18	4.16
	<b>5.18</b>	<b>4.16</b>

**8 Other assets**

	As at 31 March 2018		As at 31 March 2017	
	Non current	Current	Non current	Current
Capital advances	6.85	-	8.17	-
Prepaid expenses*	9.67	6.74	12.22	6.27
Advance to vendors	-	2.62	-	1.50
Balances recoverables from statutory authorities	-	2.45	-	-
	<b>16.52</b>	<b>11.81</b>	<b>20.39</b>	<b>7.77</b>

\*Refer note 37 for related party balances

**9 Inventories (lower of cost and net realisable value)**

	As at 31 March 2018	As at 31 March 2017
Medicinal and non medical items	12.27	11.17
	<b>12.27</b>	<b>11.17</b>

There are nil provision for written down to net realisable value.

**10 Trade receivables\***

	As at 31 March 2018	As at 31 March 2017
Considered good	17.96	18.32
Considered doubtful	4.60	2.61
	22.56	20.93
Allowance for doubtful debts (expected credit loss allowance)	(4.60)	(2.61)
	<b>17.96</b>	<b>18.32</b>
*Trade receivables include due from company in which any director is a director or a member (Refer Note 37)		
- Healthcare Global Enterprises Limited	0.10	0.10

**11 Cash and bank balances**

	As at 31 March 2018	As at 31 March 2017
(a) Cash and cash equivalents		
- Cash on hand	0.94	0.70
- Balances with banks		
In current accounts	32.33	25.30
<b>Cash and cash equivalents as per statement of cash flows</b>	<b>33.27</b>	<b>26.00</b>
(b) Bank balances other than above		
- On deposit accounts (due to maturity within 12 months of the reporting period)*	25.00	15.50
	<b>58.27</b>	<b>41.50</b>

\*The above deposits are restrictive as it pertain to margin money given against bank loan.

**12 Equity share capital**

	As at 31 March 2018	As at 31 March 2017
<b>Authorised Share capital :</b>		
300,000 equity shares of Rs.10 each (31 March 2017: 3,00,000 equity shares of Rs. 10 each)	3.00	3.00
<b>Issued, subscribed and paid up capital comprises:</b>		
93,578 fully paid equity shares of Rs.10 each (31 March 2017: 93,578 fully paid equity share of Rs.10 each)	0.94	0.94

**12.1 Reconciliation of the equity shares outstanding at the beginning and at the end of the year:**

	Number of shares	Rs. In million
Balance as at 01 April 2016	93,578	0.94
Issued during the year	-	-
Balance as at 31 March 2017	93,578	0.94
Issued during the year	-	-
<b>Balance as at 31 March 2018</b>	<b>93,578</b>	<b>0.94</b>

**12.2 Rights, preferences and restrictions attached to equity shares**

Fully paid equity shares, which have a par value of Rs.10, carry one vote per share and carry a right to dividends. The Company has only one class of equity share having a par value of Rs.10/- each. Holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of the equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amount. However, as on date no such preferential amount exists. The distribution will be in proportion to number of equity shares held by the shareholders.

**12.3 Details of shares held by each shareholder holding more than 5% equity shares**

	As at 31 March 2018		As at 31 March 2017	
	Number of Shares held	% holding of equity shares	Number of Shares held	% holding of equity shares
<b>Fully paid equity shares</b>				
HealthCare Global Enterprises Limited	46,883	50.10%	46,883	50.10%
Dr. Kamini A Rao	46,695	49.90%	46,695	49.90%

**13 Other equity**

	Note No	As at 31 March 2018	As at 31 March 2017
General reserve	13.1	0.60	0.60
Securities premium reserve	13.2	109.92	109.92
Retained earnings	13.3	284.91	244.23
Capital redemption reserve	13.4	0.15	0.15
Remeasurements of the defined benefit plan	13.5	0.32	0.46
		<b>395.90</b>	<b>355.36</b>

**13.1 General reserve**

	As at 31 March 2018	As at 31 March 2017
Balance at the beginning of the year	0.60	0.60
Balance at the end of the year	<b>0.60</b>	<b>0.60</b>

**13.2 Securities premium reserve**

	As at 31 March 2018	As at 31 March 2017
Balance at the beginning of the year	109.92	109.92
Premium on shares issued during the year	-	-
<b>Balance at the end of the year</b>	<b>109.92</b>	<b>109.92</b>

**13.3 Retained earnings**

	As at 31 March 2018	As at 31 March 2017
Balance at the beginning of the year	244.23	192.42
Profit for the year	39.99	51.81
Fair valuation of corporate guarantee given by holding company	0.69	-
<b>Balance at the end of the year</b>	<b>284.91</b>	<b>244.23</b>

**13.4 Capital redemption reserve**

	As at 31 March 2018	As at 31 March 2017
Balance at the beginning of the year	0.15	0.15
Movement during the year	-	-
<b>Balance at the end of the year</b>	<b>0.15</b>	<b>0.15</b>

**13.5 Remeasurements of the defined benefit plan**

	As at 31 March 2018	As at 31 March 2017
Balance at the beginning of the year	0.46	0.47
Other comprehensive income arising from remeasurement of defined benefit plan net of income tax	(0.14)	(0.01)
<b>Balance at the end of the year</b>	<b>0.32</b>	<b>0.46</b>



**14 Borrowings**

	As at 31 March 2018		As at 31 March 2017	
	Non current	Current	Non current	Current
<b>Secured - at amortised cost</b>				
Term loans				
from banks (Refer note 14.1)	17.41	31.20	15.57	31.20
Less : Amount included under "Other financial liabilities" ( refer note 15)	-	(31.20)	-	(31.20)
<b>Total</b>	<b>17.41</b>	<b>-</b>	<b>15.57</b>	<b>-</b>

**14.1 Summary of borrowing arrangements**

(i) The details of security and terms of repayment of term loans and other loans are stated below.

Terms of repayment and security	As at 31 March 2018	As at 31 March 2017
<b>Term loans from banks - Secured</b>		
<b>Non-current portion*</b>	17.41	15.57
<b>Amounts included under Current maturities of long-term debt</b>	31.20	31.20
- Secured by pari-passu charge on all assets of the Company		
- Exclusive first charge on all assets of the company		
- Corporate guarantee of HealthCare Global Enterprises Ltd		
- Interest rate: Base rate plus 1.65% p.a		
- Payable in 25 equal quarterly instalment after moratorium period of 12 months.		
* non current portion of bank debt is net of Rs. 1.02 million unamortised loan processing charges (31 March 2017: Nil)		
<b>Total</b>	<b>48.61</b>	<b>46.77</b>
<b>Non-current portion</b>	<b>17.41</b>	<b>15.57</b>
<b>Amounts included under current maturities of long-term debt</b>	<b>31.20</b>	<b>31.20</b>

**15 Other financial liabilities**

	As at 31 March 2018		As at 31 March 2017	
	Non current	Current	Non current	Current
a) Current maturities of long-term loan*	-	31.20	-	31.20
b) Interest accrued but not due	-	0.34	-	0.40
c) Payable to related parties (Refer Note 37)	-	5.40	-	3.65
d) Creditors for capital goods	-	23.41	-	2.02
e) Accrued salaries	-	1.74	-	3.46
<b>Total</b>	<b>-</b>	<b>62.09</b>	<b>-</b>	<b>40.73</b>

\*The details of interest rates, repayment and other terms are disclosed under note 14.1

The Company's exposure to liquidity risk are disclosed in note 33

**16 Provisions**

	As at 31 March 2018		As at 31 March 2017	
	Non current	Current	Non current	Current
Leave encashment	-	2.16	-	-
Gratuity (Refer note 31.2)	5.79	0.66	3.44	2.09
<b>Total</b>	<b>5.79</b>	<b>2.82</b>	<b>3.44</b>	<b>2.09</b>

**17 Deferred tax balances**

	As at	As at
	31 March 2018	31 March 2017
Deferred tax liabilities (refer note 26.2)	9.55	7.53
<b>Total</b>	<b>9.55</b>	<b>7.53</b>

**18 Other liabilities**

	As at 31 March 2018		As at 31 March 2017	
	Non current	Current	Non current	Current
(a) Advances from customers	-	5.37	-	5.79
(b) Balance due to statutory/government authorities	-	3.41	-	3.55
(c) Deferred revenue	-	1.67	-	-
(d) Rent equalisation reserve	6.94	-	5.92	-
<b>Total</b>	<b>6.94</b>	<b>10.45</b>	<b>5.92</b>	<b>9.34</b>

**19 Trade payables**

	As at	As at
	31 March 2018	31 March 2017
Trade payables to Micro, Small And Medium Enterprises Development (MSMED) (refer note 35)	-	-
Trade payables	47.46	46.13
<b>Total</b>	<b>47.46</b>	<b>46.13</b>

\* The Company's exposure to currency and liquidity risks related to trade payable is disclosed in note 33.

\* For details relating to payable to related parties, please refer note 37.

**20 Revenue from operations**

	<b>Year ended 31 March 2018</b>	<b>Year ended 31 March 2017</b>
Income from medical services	494.02	414.74
Sale of medical and non medical items	144.74	155.73
Other operating revenues	30.27	19.03
	<b>669.03</b>	<b>589.50</b>

**21 Other income**

	<b>Year ended 31 March 2018</b>	<b>Year ended 31 March 2017</b>
Interest income	1.41	4.61
Miscellaneous income	1.49	1.14
	<b>2.90</b>	<b>5.75</b>

**Interest comprises of**

Interest on bank deposits	0.94	3.67
Interest on income tax refund	0.47	0.94
	<b>1.41</b>	<b>4.61</b>

**22 Changes in inventories**

	<b>Year ended 31 March 2018</b>	<b>Year ended 31 March 2017</b>
Inventories at the beginning of the year	11.17	10.23
Inventories at the end of the year	12.27	11.17
Net (increase)	<b>(1.10)</b>	<b>(0.94)</b>

**23 Employee benefits expense**

	<b>Year ended 31 March 2018</b>	<b>Year ended 31 March 2017</b>
Salaries and wages	88.45	79.30
Contribution to provident and other funds	5.93	5.21
Staff welfare expenses	4.58	6.13
	<b>98.96</b>	<b>90.64</b>

**24 Finance costs**

	<b>Year ended 31 March 2018</b>	<b>Year ended 31 March 2017</b>
Interest on bank overdrafts and loans	3.96	4.56
Interest on defined benefit plan (refer note 31.2)	0.49	0.33
Loan processing charges	0.40	0.40
Commission on corporate guarantee	0.37	-
Bank charges	7.29	5.83
	<b>12.51</b>	<b>11.12</b>

**25 Other expenses**

	<b>Year ended 31 March 2018</b>	<b>Year ended 31 March 2017</b>
Medical consultancy charges	147.79	120.13
Lab charges	11.98	9.92
Power and fuel	9.53	7.45
House keeping and security charges	16.61	14.33
Rent (refer note 30)	59.07	50.39
Repairs to buildings	3.12	1.60
Repairs to machinery	5.10	2.86
Office maintenance & others	3.70	2.56
Insurance	1.67	1.09
Rates and taxes, excluding taxes on income	2.58	1.47
Printing and stationery	2.48	2.00
Advertisement, publicity and marketing	15.59	11.43
Travelling and conveyance	7.10	4.34
Legal and professional fees	4.33	7.24
Payment to auditors (refer note 25.1)	0.83	0.82
Telephone expenses	4.53	4.28
Donations	0.09	0.56
Provision for doubtful trade receivables and deposits	1.99	2.14
Miscellaneous expenses	5.92	5.18
	<b>304.01</b>	<b>249.79</b>

**25.1 Payments to auditors**

	<b>Year ended 31 March 2018</b>	<b>Year ended 31 March 2017</b>
Audit fee	0.70	0.79
Out of pocket expenses and service tax on above	0.13	0.03
	<b>0.83</b>	<b>0.82</b>

**25.2 Corporate social responsibility**

The amount required to be spent by the Company as per Section 135 of the Companies Act 2013, during the year is Nil (2016-17: Rs 1.77 million), which has been not spent as on 31 March 2018.

**26 Income tax expense**

**26.1 Income tax recognised in the Statement of profit and loss**

**Current income tax:**

In respect of the current year

**Deferred tax**

In respect of the current year

In respect of the earlier year

**Total income tax expense recognised in the Statement of profit and loss**

	Year ended 31 March 2018	Year ended 31 March 2017
In respect of the current year	18.03	22.77
	<b>18.03</b>	<b>22.77</b>
<b>Deferred tax</b>		
In respect of the current year	0.20	1.76
In respect of the earlier year	1.89	-
	<b>2.09</b>	<b>1.76</b>
<b>Total income tax expense recognised in the Statement of profit and loss</b>	<b>20.12</b>	<b>24.53</b>

The reconciliation between the income tax expense and amounts computed by applying the Indian statutory income tax rate to profit before taxes is as follows:

Profit before tax for the year	60.11	76.34
Enacted income tax rate in India	28%	33%
Computed expected tax expense	16.83	25.19
<b>Effect of:</b>		
Reduction in tax rates	1.26	-
Others	2.03	(0.66)
	<b>20.12</b>	<b>24.53</b>

**Income tax recognised in other comprehensive income**

Remeasurement of defined benefit plan

	(0.07)	-
	<b>(0.07)</b>	<b>-</b>

**26.2 Deferred tax balances**

Deferred tax assets

Deferred tax liability

	As at 31 March 2018	As at 31 March 2017
Deferred tax assets	6.24	5.39
Deferred tax liability	(15.79)	(12.92)
	<b>(9.55)</b>	<b>(7.53)</b>

Significant components of net deferred tax assets and liabilities for the year ended 31 March 2018 are as follows:

Deferred tax assets / (liabilities) in relation to	Opening balance	Recognised in	Recognised in other	Closing balance
		statement of profit and loss	comprehensive income	
Property, plant and equipment	(12.92)	(2.87)	-	(15.79)
Financial liabilities at amortised cost	0.38	(0.38)	-	-
Section 43B items	2.19	0.36	0.07	2.62
Provision for doubtful debts/advances	0.86	0.57	-	1.43
Other items	1.96	0.23	-	2.19
	<b>(7.53)</b>	<b>(2.09)</b>	<b>0.07</b>	<b>(9.55)</b>

Significant components of net deferred tax assets and liabilities for the year ended 31 March 2017 are as follows:

Deferred tax assets / (liabilities) in relation to	Opening balance	Recognised in	Recognised in other	Closing balance
		statement of profit and loss	comprehensive income	
Property, plant and equipment	(9.39)	(3.53)	-	(12.92)
Financial liabilities at amortised cost	0.20	0.18	-	0.38
Section 43B items	1.73	0.46	-	2.19
Provision for doubtful debts/advances	0.35	0.51	-	0.86
Other items	1.34	0.62	-	1.96
	<b>(5.77)</b>	<b>(1.76)</b>	<b>-</b>	<b>(7.53)</b>

**27 Contingent liabilities and capital commitments**

**Contingent liabilities**

The Company does not have any contingent liabilities as at 31 March 2018 and 31 March 2017

**Other litigations**

The Company is involved in other disputes, law suits and other claims including commercial matters which arise from time to time in the ordinary course of business. The Company believes that there are no such pending matters that are expected to have any material adverse effect on the financial statements

**Capital commitments**

**Particulars**

**As at 31 March 2018**      **As at 31 March 2017**

Estimated amount of contracts remaining to be executed on capital account and not provided for	0.03	33.77
--	------	-------

**28 Earnings per share**

**Year ending**      **Year ending 31 March**  
**31 March 2018**      **2017**

a. Profit for the period attributable to equity holders	39.99	51.81
b. Weighted average number of equity shares for the year	93,578.00	93,578.00
c. Nominal value of shares (in Rs.)	10.00	10.00
d. Earning per equity share Rs. per share (a/b)	427.34	553.66

**29 Segment information**

Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore 'Medical Services'. Accordingly, there are no additional disclosure to be provided under Ind AS 108, other than those already provided in the financial statements.

**Geographical information**

Geographical information analyses the company's revenue and non-current assets by the Company's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been presented based on the geographical location of the customers and segment assets has been presented based on the geographical location of the assets.

**(i) Revenue from operations**

Particulars	Year ended 31 March 2018	Year ended 31 March 2017
India	669.03	589.50
<b>Total</b>	<b>669.03</b>	<b>589.50</b>

**(ii) Non current assets\***

Particulars	Year ended 31 March 2018	Year ended 31 March 2017
India	421.79	356.58
<b>Total</b>	<b>421.79</b>	<b>356.58</b>

\*Non-current assets exclude financial instruments

**30 Leasing arrangements:**

**Operating lease arrangements**

The Company has entered into operating lease arrangements for certain facilities and office premises. The leases are non-cancellable and are for a period of 5 to 30 years and may be renewed for a further period, based on mutual agreement of the parties.

Particulars	Year ended	Year ended
	31 March 2018	31 March 2017
Rent expenses (Note 25)	59.07	50.39
	<b>59.07</b>	<b>50.39</b>

**Future non-cancellable operating lease commitments**

Particulars	As at	As at
	31 March 2018	31 March 2017
Not later than 1 year	65.12	39.69
Later than 1 year and not later than 5 years	211.23	196.20
Later than 5 years	361.23	392.96
	<b>637.58</b>	<b>628.85</b>

**31 Employee benefit plans**

**31.1 Defined contribution plans**

The Company has defined contribution plan in form of Provident Fund and Employee State Insurance Scheme for qualifying employees. Under the Schemes, the Company is required to contribute a specified percentage of the payroll costs to fund the benefits. The total expense recognised in the Statement of profit and loss in respect of such schemes are given below:

Particulars	Year ended	Year ended
	31 March 2018	31 March 2017
Contribution, included under contribution to provident and other funds	4.53	4.22
Contribution, included under salaries and benefits	1.13	0.63
	<b>5.66</b>	<b>4.85</b>

**31.2 Defined benefit plans**

The Company offers gratuity plan for its qualified employees which is payable as per the requirements of Payment of Gratuity Act, 1972. The benefit vests upon completion of five years of continuous service and once vested it is payable to employees on retirement or on termination of employment. In case of death while in service, the gratuity is payable irrespective of vesting.

The principal assumptions used for the purposes of the actuarial valuations were as follows:

	Valuation as at	
	31 March 2018	31 March 2017
Discount rate	8%	6%
Expected rate of salary increase	6%	6%
Rate of return on plan assets	NA	NA
Employee turnover rate	47%	39%

Amounts recognised in standalone statement of profit and loss in respect of this defined benefit plan are as follows:

	Year ended	Year ended
	31 March 2018	31 March 2017
Current service cost	1.40	0.99
Net interest expense	0.49	0.33
<b>Components of defined benefit costs recognised in the Statement of profit and loss</b>	<b>1.89</b>	<b>1.32</b>
Service cost recognised in employee benefits expense in note 23	1.40	0.99
Net interest expense recognised in finance costs in note 24	0.49	0.33

**Remeasurement on the net defined benefit liability:**

Actuarial (gains) / losses arising from changes in demographic assumptions	(0.18)	-
Actuarial (gains) / losses arising from changes in financial assumptions	(0.19)	0.26
Actuarial (gains) / losses arising from experience adjustments	0.58	(0.25)
Remeasurement on plan assets	-	-
Adjustments for restrictions on the defined benefit asset	-	-
<b>Remeasurement on the net defined benefit liability recognised in other comprehensive income</b>	<b>0.21</b>	<b>0.01</b>

The amount included in the standalone balance sheet arising from the entity's obligation in respect of its defined benefit plans is as follows:

	As at	As at
	31 March 2018	31 March 2017
Present value of funded defined benefit obligation	6.45	5.54
Fair value of plan assets	-	-
<b>Unfunded status</b>	<b>6.45</b>	<b>5.54</b>
Restrictions on asset recognised	-	-
<b>Net liability arising from defined benefit obligation</b>	<b>6.45</b>	<b>5.54</b>

Movements in the present value of the defined benefit obligation are as follows:

	As at	As at
	31 March 2018	31 March 2017
Opening defined benefit obligation	5.54	4.28
Current service cost	1.40	0.99
Interest cost	0.49	0.33
<b>Remeasurement (gains)/losses:</b>		
Actuarial gains and losses arising from changes in demographic assumptions	(0.18)	-
Actuarial gains and losses arising from changes in financial assumptions	(0.19)	0.26
Actuarial gains and losses arising from experience adjustments	0.58	(0.25)
Effect of acquisition	(0.01)	0.11
Benefits paid	(1.18)	(0.18)
<b>Closing defined benefit obligation</b>	<b>6.45</b>	<b>5.54</b>

Particulars	As at 31 March 2018		As at 31 March 2017	
	Increase	Decrease	Increase	Decrease
Discount rate (1% change)	(0.39)	0.44	(0.01)	0.02
Future salary increase (1% change)	0.46	(0.41)	0.01	(0.01)
Attrition rate (10% change)	0.01	0.02	(0.01)	0.02

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation.

There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

The average duration of the benefit obligation at 31 March 2018 is 10.68 years (31 March 2017 1.96 years)

Maturity profile of defined benefit obligation:

Particulars	As at	As at
	31 March 2018	31 March 2017
Within 1 year	0.66	2.00
1-2 years	0.68	1.33
2-3 years	0.74	0.92
3-4 years	0.74	0.68
4-5 years	0.80	0.48
6-10 years	3.14	0.86
Year 10+	5.02	-

**32 Financial instruments**

The carrying value and fair value of financial instruments by categories as at 31 March 2018 and 31 March 2017 is as follows:

Particulars	Carrying value as at	
	31 March 2018	31 March 2017
<b>Financial assets</b>		
<b>Amortised cost</b>		
Loans (includes current and non-current)	26.16	23.90
Trade receivables	17.96	18.32
Cash and bank balances	58.27	41.50
Other financial assets (includes current and non-current)	11.09	27.81
<b>Total assets</b>	<b>113.48</b>	<b>111.53</b>
<b>Financial liabilities</b>		
<b>Amortised cost</b>		
Borrowings (including current maturities and short-term borrowings)	48.61	46.77
Trade payables	47.46	46.13
Other financial liabilities (includes current and non-current)	30.89	9.53
<b>Total liabilities</b>	<b>126.96</b>	<b>102.43</b>

The management assessed that fair value of above financial assets and liabilities approximate their carrying amounts.

Refer note 14.1 for details related to charge on financial assets.

**33 Financial risk management**

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk and price risks which may adversely impact the fair value of its financial instruments. The Company has a risk management committee which covers risks associated with the financial assets and liabilities. The focus of risk management committee is to assess the unpredictability of the financial environment and to mitigate potential adverse effects on the financial performance of the Company.

**Credit risk**

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to the credit risk from its trade receivables, cash and cash equivalents, bank deposits and other financial assets. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses in financial assets.

*a) Trade and other receivables*

Trade receivables comprise a widespread customer base. Management evaluate credit risk relating to customers on an ongoing basis. If customers are independently rated, these ratings are used. Otherwise, if there is no independent rating, risk control assesses the credit quality of the customer, taking into account its financial position, past experience and other factors. Individual risk limits are set for patients without medical aid insurance. Services to customers without medical aid insurance are settled in cash or using major credit cards on discharge date as far as possible. Credit Guarantees insurance is not purchased. The receivables are mainly unsecured, the Company does not hold any collateral or a guarantee as security. The provision details of the trade receivable is provided in Note 10.1 of the financial statement.

The Company has used a practical expedient by computing the expected credit loss allowance for trade receivables based on a provision matrix. The provision matrix takes into account historical credit loss experience and adjusted for forward looking information. The expected credit loss allowance is based on the ageing of the days the receivables are due and the rates as derived as per the trend of trade receivable ageing of previous years.

Movement in the expected credit loss allowance

	Year ended 31 March 2018	Year ended 31 March 2017
Balance at beginning of the year	2.61	0.47
Additional provision during the year	1.99	2.14
<b>Balance at end of the year</b>	<b>4.60</b>	<b>2.61</b>

The Company's exposure to customers is diversified. No single customer contributes to more than 10% of the outstanding receivable and unbilled revenue as of 31 March 2018, 31 March 2017 and 01 April 2016.

Geographic concentration of credit risk: The group has a geographic concentration of trade receivables in India.

*b) Investments and cash deposits*

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors.

**Liquidity risk**

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due. Also, the Company has unutilized credit limits with banks.

The Company's corporate treasury department is responsible for liquidity, funding as well as settlement management. In addition, processes and policies related to such risks are overseen by senior management.

The table below provides details regarding the contractual maturities of significant financial liabilities as at 31 March 2018 and 31 March 2017:

Particulars	As at 31 March 2018				
	Less than				5 years
	1 year	1-2 years	2-3 years	3-4 years	and above
Borrowings	31.20	17.41	-	-	-
Trade payables	47.46	-	-	-	-
Other financial liabilities	30.89	-	-	-	-

  

Particulars	As at 31 March 2017				
	Less than				5 years
	1 year	1-2 years	2-3 years	3-4 years	and above
Borrowings	31.20	15.57	-	-	-
Trade payables	46.13	-	-	-	-
Other financial liabilities	9.53	-	-	-	-

**Market risk:**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices, such as foreign exchange rates, interest rates and equity prices.

*Cash flow and fair value interest rate risk*

The Company's main interest rate risk arises from long-term borrowings with variable rates, which expose the Company to cash flow interest rate risk.

a. Interest rate risk exposure

The exposure of the Company's borrowing to interest rate changes at the end of the reporting period are as follows:

Particulars	31 March 2018	31 March 2017
Variable rate long term borrowings including current maturities	49.63	46.77
<b>Total borrowings</b>	<b>49.63</b>	<b>46.77</b>

b. Sensitivity analysis

Every 1% increase or decrease in base rate does not have material impact to statement of profit and loss and other components of equity.

34 Pursuant to the MCA notification G.S.R. 308(E) dated 30 March 2017, the details of Specified Bank Notes (SBN)\* held and transacted during the period from 8 November 2016 to 30 December 2016 are provided in the table below:

Particulars	SBNs	Other denomination notes	Total
Closing cash in hand as on 8 November 2016	1.17	0.09	1.26
(+) Permitted receipts	5.16	7.08	12.24
(-) Permitted payments	-	(0.15)	(0.15)
(-) Amount deposited in Banks	(6.33)	(6.18)	(12.51)
Closing cash in hand as on 30 December 2016	-	0.84	0.84

\* The term 'Specified Bank Notes' have the same meaning provided in the notification of the Government of India, in the Ministry of Finance, Department of Economic Affairs number S.O. 3407(E), dated the 8 November 2016.



**35 Due to micro, Small and medium enterprises**

The Ministry of Micro, Small and Medium Enterprises has issued an office memorandum dated 26 August 2008 which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum. Accordingly, the disclosure in respect of the amounts payable to such enterprises as at 31 March 2018 has been made in the financial statements based on information received and available with the Company. Further in view of the management, the impact of interest, if any, that may be payable in accordance with the provisions of the Micro, Small and Medium Enterprises Development Act, 2006 ('The MSMED Act') is not expected to be material. The Company has not received any claim for interest from any supplier:

Particulars	As at 31 March 2018	As at 31 March 2017
The amounts remaining unpaid to micro and small suppliers as at the end of the year		
Principal	-	-
Interest	-	-
The amount of interest paid by the buyer under MSMED Act	-	-
The amount of payments made to micro and small suppliers beyond the appointed day during the accounting year	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act;	-	-
The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under the MSMED Act	-	-

**36 Capital management**

The Company manages its capital to ensure that entities in the Company will be able to continue as going concerns while maximising the return to stakeholders through the optimisation of the debt and equity balance. The capital structure of the Company consists of net debt (borrowings offset by cash and bank balances) and total equity of the Company.

The capital structure is as follows:

Particulars	As at 31 March 2018	As at 31 March 2017
Total equity attributable to the equity share holders of the company	396.84	356.30
As percentage of total capital	96%	94%
Current Borrowings	31.20	31.20
Non-current loans and borrowings	17.41	15.57
Total loans and borrowings	48.61	46.77
Cash and Bank Balances	33.27	26.00
Net loans and borrowings	15.34	20.77
As a percentage of total capital	4%	6%
<b>Total capital (borrowings and equity)</b>	<b>412.18</b>	<b>377.07</b>

### 37 Related Party Disclosure

Details of related parties:

Description of relationship	Names of related parties
Holding Company (HC)	HealthCare Global Enterprises Limited
Firm in which one of the director is a partner	Konnect 6
HUF - Director is a Kartha	BACC Pharma
Key Management Personnel (KMP)	<b>Non-executive directors</b> Dr.Kamini A Rao Dr.A S Aravind Rao Dr.B.S Ajaikumar Gangadhara Ganapati

Details of related party transactions during the year ended 31 March 2018 and balances outstanding as at 31 March 2017

Particulars	Year ended 31 March 18	Year ended 31 March 17
<b>Lab charges expense</b>		
- Healthcare Global Enterprises Limited	0.31	1.47
<b>Medical consultancy charges</b>		
- Dr. Kamini A Rao	18.98	16.50
- A.S. Arvind Rao	5.50	5.50
<b>Capital contribution (Corporate guarantee) received during the year</b>		
- Healthcare Global Enterprises Limited	49.63	-
<b>Corporate guarantee commission</b>		
- Healthcare Global Enterprises Limited	0.69	-
<b>Corporate guarantee commission charges</b>		
- Healthcare Global Enterprises Limited	0.37	-
<b>Capital expenditure/ revenue expenditure reimbursed repayed</b>		
- Healthcare Global Enterprises Limited	1.84	2.88
<b>Rent Payment</b>		
- Dr. Kamini A Rao	0.66	0.64

Details of related party balances outstanding:

Balances outstanding as at	As at 31 March 2018	As at 31 March 2017
<b>Trade payables</b>		
- Healthcare Global Enterprises Limited	0.08	0.13
<b>Trade receivables</b>		
- Healthcare Global Enterprises Limited	0.10	0.10
<b>Corporate guarantees</b>		
- Healthcare Global Enterprises Limited	49.63	-
<b>Other current assets- Corporate guarantee commission</b>		
- Healthcare Global Enterprises Limited	0.32	-
<b>Other financial liabilities - current</b>		
- Healthcare Global Enterprises Limited	5.50	3.65

Note:

All transactions with the related parties are priced at arm's length basis and resulting outstanding balances are to be settled as per the terms agreed. None of the above balances are secured.

**38 Merger of DKR Healthcare Private Limited**

During the year, DKR HealthCare Private Limited the wholly owned subsidiary of the Company (Transferor Company), has been merged with the Company (Transferee Company) in accordance with the terms of a Scheme of Amalgamation (the Scheme) as approved by the Regional Director, Ministry of Corporate affairs, Bangalore with an appointed date of 01 April 2017. The merger has been accounted under the pooling of interest method and the assets and liabilities transferred were recorded at their book values.

Pursuant to the Scheme, the Company's investment of 200,000 shares of Rs.10/- each in its subsidiary DKR HealthCare Private Limited has been cancelled against share capital of DKR HealthCare Private Limited

As prescribed in Appendix C of Ind AS 103, 'Business Combination, this being a common control entity, the financial statement of the Company has been re-stated from the beginning of the preceding period, i.e. 1 April 2016. Accordingly, excess of investment over share capital has been credited to opening reserves as of 01 April 2016.

The book value of assets and liabilities taken over as on 01 April 2016 are as follows

<b>Particulars</b>	<b>1 April 2016</b>
<b>Non-current assets</b>	
Property, plant and equipment	20.71
Other financial assets	1.79
	22.50
<b>Current Asset</b>	
Inventories	1.21
Trade receivables	0.42
Cash and cash equivalents	18.09
Other financial assets	0.41
	20.13
<b>Total Assets</b>	<b>42.63</b>
<b>Non-current liabilities</b>	
Provision	0.07
Deferred tax liabilities	1.56
	1.63
<b>Current liabilities</b>	
Other financial liabilities	0.28
Borrowings	8.48
Trade payables	14.23
Other liabilities	0.71
	23.70
<b>Total liabilities</b>	<b>25.33</b>
<b>Net assets/ (liabilities) taken over</b>	<b>17.30</b>
Investment of the Company in DKR Healthcare Private Limited	8.50
<b>Adjusted towards reserves</b>	<b>8.80</b>

Pursuant to the Scheme, all the assets and liabilities of DKR HealthCare Private Limited are translated and vested into the Company from 01 April 2016 i.e the beginning of the preceeding financial period. Accordingly, the comparative financial information for the year ended 31 March 2017 has been restated to include the aassets and liabilities as at 31 March 2017 and operations for the year ended 31 Match 2017 of DKR HealthCare Private Limited.

*for* **B S R & Co. LLP**  
*Chartered Accountants*  
Firm's registration number: 101248W/W -100022

*for* and on behalf of the Board of Directors of  
**BACC Health Care Private Limited**

**Amit Somani**  
*Partner*  
Membership Number: 060154

**Dr. B S Ajaikumar**  
Director  
DIN: 00713779

**Dr. Kamini A.Rao**  
Director  
DIN: 01075263

Place : Bengaluru  
Date : 8 August 2018

Place : Bengaluru  
Date : 8 August 2018

Place : Bengaluru  
Date : 8 August 2018